Evidence map›Paper›PMID 36830949›Full record

ReviewBiomedicines2023

Nanotechnology as a Promising Approach to Combat Multidrug Resistant Bacteria: A Comprehensive Review and Future Perspectives.

Helal F Hetta, Yasmin N Ramadan, Alhanouf I Al-Harbi, Esraa A Ahmed, Basem Battah, Noura H Abd Ellah, Stefania Zanetti, Matthew Gavino Donadu

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Biomedicines, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 128 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
128citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

128 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Glucosamine functionalized multi-walled carbon nanotubes as potential antibacterial molecules.International microbiology : the official journal of the Spanish Society for Microbiology · 2026
    Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. Review

68 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Helal F HettaDepartment of Medical Microbiology and Immunology, Faculty of Medicine, Assiut University, Assiut 71515, Egypt.ORCID 0000-0001-8541-7304
Yasmin N RamadanDepartment of Microbiology and Immunology, Faculty of Pharmacy, Assiut University, Assiut 71515, Egypt.
Alhanouf I Al-HarbiDepartment of Medical Laboratory, College of Applied Medical Sciences, Taibah University, Yanbu 46411, Saudi Arabia.ORCID 0000-0003-0889-2886
Esraa A AhmedDepartment of Pharmacology, Faculty of Medicine, Assiut University, Assiut 71515, Egypt.
Basem BattahDepartment of Biochemistry and Microbiology, Faculty of Pharmacy, Syrian Private University (SPU), Daraa International Highway, 36822 Damascus, Syria.
Noura H Abd EllahDepartment of Pharmaceutics, Faculty of Pharmacy, Assiut University, Assiut 71515, Egypt.
Stefania ZanettiDepartment of Biomedical Sciences, University of Sassari, 07100 Sassari, Italy.
Matthew Gavino DonaduDepartment of Biomedical Sciences, University of Sassari, 07100 Sassari, Italy.ORCID 0000-0001-7681-6194

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The wide spread of antibiotic resistance has been alarming in recent years and poses a serious global hazard to public health as it leads to millions of deaths all over the world. The wide spread of resistance and sharing resistance genes between different types of bacteria led to emergence of multidrug resistant (MDR) microorganisms. This problem is exacerbated when microorganisms create biofilms, which can boost bacterial resistance by up to 1000-fold and increase the emergence of MDR infections. The absence of novel and potent antimicrobial compounds is linked to the rise of multidrug resistance. This has sparked international efforts to develop new and improved antimicrobial agents as well as innovative and efficient techniques for antibiotic administration and targeting. There is an evolution in nanotechnology in recent years in treatment and prevention of the biofilm formation and MDR infection. The development of nanomaterial-based therapeutics, which could overcome current pathways linked to acquired drug resistance, is a hopeful strategy for treating difficult-to-treat bacterial infections. Additionally, nanoparticles' distinct size and physical characteristics enable them to target biofilms and treat resistant pathogens. This review highlights the current advances in nanotechnology to combat MDR and biofilm infection. In addition, it provides insight on development and mechanisms of antibiotic resistance, spread of MDR and XDR infection, and development of nanoparticles and mechanisms of their antibacterial activity. Moreover, this review considers the difference between free antibiotics and nanoantibiotics, and the synergistic effect of nanoantibiotics to combat planktonic bacteria, intracellular bacteria and biofilm. Finally, we will discuss the strength and limitations of the application of nanotechnology against bacterial infection and future perspectives.

Indexed as

biofilmMDR bacteriananoantibioticsnanotechnologyXDR bacteria

Identifiers

PMID36830949
PMCPMC9953167

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.